ROSEVILLE, Minn., Sept. 6, 2011 /PRNewswire/ — Today, Advanced
Circulatory Systems Inc. (ACSI) announced results from a large,
NIH-funded clinical trial comparing standard cardiopulmonary
resuscitation (CPR) to a new method of CPR that provides greater
protection to the heart and brain when the heart stops beating
(cardiac arrest). Their new device combination, called the
ResQCPR™ System, combines an active compression decompression
CPR (ACD-CPR) device, called the ResQPump™, and an impedance
threshold device (ITD), called the ResQPOD®.
Additional results from the ResQTrial study have now
demonstrated that when the ResQCPR System was used together with
therapeutic hypothermia, there was a six-fold increase in the
percentage of patients who improved from poor neurologic function
at hospital discharge to good neurologic function at 90 days, when
compared to standard CPR with hypothermia.
“The striking improvement in patients treated with the ResQCPR
System and hypothermia demonstrates the important synergy between
the two technologies. These findings provide a new way to
significantly decrease the number of patients with poor long-term
neurological function, especially when the ResQCPR System is
applied early during cardiac arrest,” Said Dr. Marvin Wayne,
EMS Medical Director of Whatcom County in Washington, and principal
author of the study.
The ResQTrial Study evaluated over 5,000 patients in seven
different US emergency medical services (EMS) systems to determine
the effect of the ResQCPR System on rates of long-term survival
with good brain function. The new findings from the study focus on
the subset of patients with poor brain function (neurologic
outcomes) at the time of hospital discharge. Poor neurological
function for survivors after cardiac arrest is an enormous burden
for families, patients, and society due to the high health care
costs associated with caring for them. About 25 percent of
the
‘/>”/>
